KAM
VKTX icon

Kazazian Asset Management’s Viking Therapeutics VKTX Stock Holding History

Kazazian Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-11,703
Closed -$90K – 68
2018
Q4 		$90K Sell
11,703
-7,089
-38% -$84.8K 0.12% 60
2018
Q3 		$327K Buy
+18,792
New +$224K 0.31% 60

Other funds holding VKTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Kazazian Asset Management's VKTX Position: Q1 2019 in Review

Kazazian Asset Management sold out of Viking Therapeutics (VKTX) in Q1 2019, closing a stake of 11,703 shares — an estimated $90K sold.

Kazazian Asset Management first reported a position in VKTX in Q3 2018 and held it in 2 quarters. The position peaked at $327K in Q3 2018. 164 funds tracked by Wall St. Rank hold VKTX as of Q1 2019.

  • Kazazian Asset Management reported no remaining Viking Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Kazazian Asset Management sold 11,703 Viking Therapeutics shares in Q1 2019, an estimated $90K.
  • Kazazian Asset Management first reported a position in Viking Therapeutics in Q3 2018 and held it in 2 quarters.
  • Kazazian Asset Management's Viking Therapeutics position peaked at $327K in Q3 2018.
  • 164 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2019.

Based on Kazazian Asset Management's 13F filing for Q1 2019, filed 15 May 2019.